In addition, pretreatment CAR was positively correlated with sex, location of the primary tumor, pretreatment CEA and CA19-9, and stage and negatively correlated with pathological differentiation in CRC patients (Table 1). This evidence concerns the gene CEACAM5 and neoplasm.